TY  - JOUR
TI  - Personalized Phage Therapy for Drug-Resistant and Difficult-to-Treat Bacterial Infections: A Systematic Review of Human Clinical Evidence and Narrative Synthesis
AU  - A.G. Shamsutdinova
AU  - D.S. Menlyakova
AU  - B.O. Minbaev
AU  - G.B. Ensebaeva
JO  - Global Medical Reviews
PY  - 2026
DA  - 2026-07-27
VL  - 1
IS  - 1
SP  - e0005
KW  - bacteriophage therapy
KW  - personalized phage therapy
KW  - antimicrobial resistance
KW  - multidrug resistance
KW  - phage susceptibility testing
KW  - antiphage immunity
AB  - Background: Personalized bacteriophage therapy selects, adapts, or engineers a phage preparation against a patient clinical isolate. This biological specificity may improve target engagement but complicates standardization and causal inference. Objective: To evaluate human clinical evidence on personalized or strain-matched phage therapy and distinguish direct personalized evidence from indirect randomized evidence generated with fixed phage preparations. Methods: The review was structured according to PRISMA 2020. Seven bibliographic and trial sources plus citation searches were assessed through 8 July 2026. Results: Thirteen reports representing 10 study datasets were included. Personalized series showed repeated clinical and microbiological signals, but effectiveness certainty remained very low. Conclusions: The most defensible clinical model is adjunctive precision infectious-disease care combining a matched, quality-controlled phage preparation with optimized antibacterial therapy, source control, and longitudinal monitoring.
UR  - https://glr.sciences.kz/article/personalized-phage-therapy
L2  - https://glr.sciences.kz/downloads/GMR_2026_1_1_e0005_personalized-phage-therapy.pdf
ER  -